BRIEF—Chugai's Enspryng launched in Taiwan as first indicated for NMOSD

Chugai Pharmaceutical says that it launched Enspryng (satralizumab) in Taiwan on October 1 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent over 12 years old patients who are anti-aquaporin-4 (AQP4) antibody positive” as the first indication in Taiwan.

Enspryng was created by Chugai, which is majority-owned by Swiss pharma giant Roche.

Enspryng was designated as an orphan drug Ministry of Health and Welfare (MoHW) on September 14, 2022, and approved orphan drug license by Taiwan Food and Drug Administration (TFDA) on July 28, 2023.

Enspryng has been approved for the treatment of NMOSD in more than 85 countries including Japan, the USA the European Union.